Importantly, even after adjusting for standard clinicopathological factors, medium pSMAD2 remained an independent predictor of increased recurrence risk, indicating that attenuation of TGF-β signaling may serve as a prognostic marker at early breast cancer stages. Here, TGFB1 is linked to breast carcinoma.